Objectives To determine the incidence of ALK translocations in patients with
advanced/metastatic NSCLC in Spain, to describe the clinical characteristics of these …

Lorlatinib is an oral third-generation inhibitor of anaplastic lymphoma kinase (ALK) with
activity in advanced ALK-positive non-small cell lung cancer (NSCLC) in both the first and …

The emergence of tyrosine kinase inhibitors and immune checkpoint inhibitors has paved a
new era for the management of non‐small cell lung cancer, which has for many years lacked …

Precision oncology has fundamentally changed how we diagnose and treat cancer. In
recent years, there has been a significant change in the management of patients with …

Crizotinib is a clinically approved tyrosine kinase inhibitor for the treatment of patients with
locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EML4-ALK …

Background Brigatinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor with
demonstrated efficacy in locally advanced and metastatic non–small cell lung cancer …

Purpose Patients with non‐small cell lung cancer (NSCLC) that harbor driver mutations are
associated with a cancer diagnosis at a younger age. While targeted therapies provide deep …

Background Granulocyte colony-stimulating factor (G-CSF)-producing lung cancer induces
severe inflammation and a high white blood cell (WBC) count and is associated with poor …

For advanced cancers of the digestive system, personalized, precise treatment can be life
saving. With the development of next-generation sequencing technology, detection of fusion …

Identifying molecular oncogenic drivers is crucial for precision oncology. Genetic
rearrangements, including gene fusions and gene amplification, involving and activating …